Literature DB >> 23416700

Central administration of angiotensin IV rapidly enhances novel object recognition among mice.

Jason J Paris1, Shainnel O Eans, Elisa Mizrachi, Kate J Reilley, Michelle L Ganno, Jay P McLaughlin.   

Abstract

Angiotensin IV (Val(1)-Tyr(2)-Ile(3)-His(4)-Pro(5)-Phe(6)) has demonstrated potential cognitive-enhancing effects. The present investigation assessed and characterized: (1) dose-dependency of angiotensin IV's cognitive enhancement in a C57BL/6J mouse model of novel object recognition, (2) the time-course for these effects, (3) the identity of residues in the hexapeptide important to these effects and (4) the necessity of actions at angiotensin IV receptors for procognitive activity. Assessment of C57BL/6J mice in a novel object recognition task demonstrated that prior administration of angiotensin IV (0.1, 1.0, or 10.0, but not 0.01 nmol, i.c.v.) significantly enhanced novel object recognition in a dose-dependent manner. These effects were time dependent, with improved novel object recognition observed when angiotensin IV (0.1 nmol, i.c.v.) was administered 10 or 20, but not 30 min prior to the onset of the novel object recognition testing. An alanine scan of the angiotensin IV peptide revealed that replacement of the Val(1), Ile(3), His(4), or Phe(6) residues with Ala attenuated peptide-induced improvements in novel object recognition, whereas Tyr(2) or Pro(5) replacement did not significantly affect performance. Administration of the angiotensin IV receptor antagonist, divalinal-Ang IV (20 nmol, i.c.v.), reduced (but did not abolish) novel object recognition; however, this antagonist completely blocked the procognitive effects of angiotensin IV (0.1 nmol, i.c.v.) in this task. Rotorod testing demonstrated no locomotor effects with any angiotensin IV or divalinal-Ang IV dose tested. These data demonstrate that angiotensin IV produces a rapid enhancement of associative learning and memory performance in a mouse model that was dependent on the angiotensin IV receptor.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416700      PMCID: PMC3742075          DOI: 10.1016/j.neuropharm.2013.01.025

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  60 in total

1.  Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus.

Authors:  J W Harding; V I Cook; A V Miller-Wing; J M Hanesworth; M F Sardinia; K L Hall; J W Stobb; G N Swanson; J K Coleman; J W Wright
Journal:  Brain Res       Date:  1992-06-26       Impact factor: 3.252

2.  Spatial memory, recognition memory, and the hippocampus.

Authors:  Nicola J Broadbent; Larry R Squire; Robert E Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-27       Impact factor: 11.205

3.  6-OHDA lesions to amygdala and hippocampus attenuate memory-enhancing effect of the 3-7 fragment of angiotensin II.

Authors:  M M Winnicka; J J Braszko; K Wiśniewski
Journal:  Gen Pharmacol       Date:  1998-05

4.  Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist.

Authors:  L T Krebs; E A Kramár; J M Hanesworth; M F Sardinia; A E Ball; J W Wright; J W Harding
Journal:  Regul Pept       Date:  1996-12-03

5.  Central angiotensin IV binding sites: distribution and specificity in guinea pig brain.

Authors:  A V Miller-Wing; J M Hanesworth; M F Sardinia; K L Hall; J W Wright; R C Speth; K L Grove; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

6.  Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse.

Authors:  Amanda N Carey; Elizabeth I Sypek; Harminder D Singh; Marc J Kaufman; Jay P McLaughlin
Journal:  Behav Brain Res       Date:  2011-12-20       Impact factor: 3.332

7.  Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats.

Authors:  J Lee; A L Albiston; A M Allen; F A O Mendelsohn; S E Ping; G L Barrett; M Murphy; M J Morris; S G McDowall; S Y Chai
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

8.  Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity.

Authors:  Leen H Kawas; Brent J Yamamoto; John W Wright; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

Review 9.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Birks
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 10.  Cognitive-enhancing effects of angiotensin IV.

Authors:  Paul R Gard
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more
  10 in total

1.  Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease.

Authors:  Arndt Manzel; Oliver Domenig; Bjoern Ambrosius; Agnes Kovacs; Johannes Stegbauer; Marko Poglitsch; Dominik N Mueller; Ralf Gold; Ralf A Linker
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-23       Impact factor: 4.147

Review 2.  Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets.

Authors:  Jessika Royea; Edith Hamel
Journal:  Geroscience       Date:  2020-07-22       Impact factor: 7.713

3.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

4.  Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.

Authors:  Christina J Schier; William D Marks; Jason J Paris; Aaron J Barbour; Virginia D McLane; William F Maragos; A Rory McQuiston; Pamela E Knapp; Kurt F Hauser
Journal:  J Neurosci       Date:  2017-05-04       Impact factor: 6.167

5.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

Review 6.  Integrative Physiological Aspects of Brain RAS in Hypertension.

Authors:  Sharon D B de Morais; Julia Shanks; Irving H Zucker
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

7.  Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.

Authors:  Yun K Hahn; Jason J Paris; Aron H Lichtman; Kurt F Hauser; Laura J Sim-Selley; Dana E Selley; Pamela E Knapp
Journal:  Neurobiol Dis       Date:  2016-02-01       Impact factor: 5.996

8.  Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.

Authors:  Jean K Ho; Daniel A Nation
Journal:  Neurosci Biobehav Rev       Date:  2018-05-04       Impact factor: 8.989

Review 9.  The Renin-Angiotensin System in Huntington's Disease: Villain or Hero?

Authors:  Thatiane C G Machado; Cristina Guatimosim; Lucas M Kangussu
Journal:  Protein Pept Lett       Date:  2020       Impact factor: 1.890

10.  Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion.

Authors:  Qing-Guang Wang; Xiao Xue; Yang Yang; Peng-Yu Gong; Teng Jiang; Ying-Dong Zhang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.